Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Weight-Loss Drugs Are Everywhere Now. How the GLP-1 Copycats Took Over.
Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.
Weight Loss From GLP-1 Drugs Not As Robust In Real-World Settings
In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and weight loss not meeting patients' expectations.
GLP-1 weight-loss meds might interfere with endoscopy, colonoscopy
Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or stool left in the bowel before an endoscopy or colonoscopy.
3 More Benefits GLP-1 Drugs Like Ozempic May Provide in Addition to Weight Loss
New research suggests GLP-1 medications like Ozempic may help reduce several health risks in addition to treating type 2 diabetes and obesity.
Eli Lilly’s Weight-Loss, Diabetes Drug Shortages Are Over, FDA Says
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines.
England's NHS to offer Lilly's weight-loss drug to some patients
England's National Health Services will offer Eli Lilly's weight-loss drug to nearly a quarter million people as part of a three-year plan, the country's drugs cost regulator said on Thursday. The drug,
The FDA issued a warning about compounding pharmacies on weight-loss drugs
A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies against skirting regulatory standards to put them on the market now that shortages are waning.
What end of Eli Lilly's weight-loss drug shortage means for the competition
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses to meet current demand.
Zepbound is no longer in shortage. That could hurt off-brand weight loss drug sellers
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food and Drug Administration (FDA).
6d
on MSN
GLP-1 supplements promise to curb cravings and promote weight loss. Experts are skeptical.
Kourtney Kardashian’s vitamin and supplement brand Lemme launched GLP-1 daily capsules in mid-September. For $90 a month, the ...
Glamour on MSN
3d
Do GLP-1 Supplements Work? Doctors Set the Record Straight on ‘Nature’s Ozempic’
Brands like Kourtney Kardashian’s Lemme are claiming to provide the same benefits as GLP-1 medications like Ozempic, Wegovy, ...
Psychology Today
6d
GLP-1 Agonists May Help Treatment of Mental Illness and Substance Use
Agents like semaglutide show promise for treatment of substance use disorders. Inaccessibility of GLP-1 agonists due to high ...
anesthesiologynews
1h
Debate: Is ASA Guidance on Preoperative GLP-1 Agonists Good Enough?
As more Americans are prescribed glucagon-like peptide-1 receptor agonist drugs, concerns are rising about how to best manage associated adverse ...
FiercePharma
16h
Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...
4d
GLP-1 medications, their effect on bariatrics and cautions for people seeking weight loss without surgery
Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...
MedPage Today
6d
Food Retention Risk Low for GLP-1 Users When Endoscopy Is Combined With Colonoscopy
"There is a clear association between the use of GLPs and increased risks of food retention during upper endoscopy," Mathur ...
Business Wire
4d
Digbi Health to Present Groundbreaking Study on Gut Microbiome's Role in Enhancing Endogenous GLP-1 Production at 2024 Obesity Society Conference
Digbi Health, a leader in Precision Biology and personalized healthcare, has been invited to present a landmark study at the ...
News Medical on MSN
2h
GLP-1 drugs protect brain health by improving neurovascular function and reducing inflammation
Research highlights how GLP-1 receptor agonists may improve brain health by targeting the neurovascular unit, linking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Ozempic
Novo Nordisk
Eli Lilly and Company
Feedback